Navigating the Challenges of Invasive Pulmonary Aspergillosis in Lung Cancer Treatment: a Propensity Score Study

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2023 Sep 18

PMID 37720497

Authors

Chin-Wei Kuo

Chien-Yu Lin

Sheng-Huan Wei

Yun-Tse Chou

Chian-Wei Chen

Jeng-Shiuan Tsai

Po-Lan Su

Chien-Chung Lin

Affiliations

Soon will be listed here.

Abstract

Background: Invasive pulmonary aspergillosis (IPA) can negatively impact cancer patients' survival. It remains uncertain whether IPA's impact on patient outcomes varies by treatment approach in advanced lung cancer.

Objectives: To explore the association between IPA and outcomes in patients with advanced lung cancer receiving different treatments.

Design: A retrospective cohort study.

Methods: We enrolled patients with advanced-stage lung cancer between 2013 and 2021 at a college hospital in Taiwan and used the 2021 European Organization for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium consensus for IPA diagnosis. Multivariable logistic regression was used to identify the IPA risk factors. We compared overall survival (OS) and postgalactomannan (GM) test survival between the IPA and control groups using multivariable Cox proportional hazards regression and the Kaplan-Meier method with propensity score matching (PSM).

Results: Among 2543 patients with advanced-stage lung cancer, 290 underwent a GM test, of which 34 (11.7%) were diagnosed with IPA. Patients undergoing chemotherapy (HR = 4.02, = 0.027) and immunotherapy [hazard ratio (HR) = 3.41, = 0.076] tended to have IPA. Compared to the control group, the IPA group had shorter median OS (14.4 9.9 months, = 0.030) and post-GM test survival (4.5 1.9 months, = 0.003). IPA was associated with shorter OS (log-rank = 0.014 and 0.018 before and after PSM, respectively) and shorter 1-year and 2-year survival post-GM test (HR = 1.65 and 1.66, respectively). Patients receiving chemotherapy or immunotherapy had a shorter post-GM test survival if they had IPA.

Conclusions: IPA tended to be diagnosed more frequently in patients receiving chemotherapy or immune checkpoint inhibitors. Patients diagnosed with IPA are associated with shorter survival. Larger cohort studies are needed to verify the observations.

Citing Articles

Metagenomic next-generation sequencing and galactomannan testing for the diagnosis of invasive pulmonary aspergillosis.

Yang J, Wu X, Zhang Q, Lin C, Yu Y, Zhang X Sci Rep. 2024; 14(1):31389.

PMID: 39732910 PMC: 11682328. DOI: 10.1038/s41598-024-82806-9.

Mapping the Burden of Fungal Diseases in the United Arab Emirates.

Dhaheri F, Thomsen J, Everett D, Denning D J Fungi (Basel). 2024; 10(5).

PMID: 38786708 PMC: 11121979. DOI: 10.3390/jof10050353.

References

Cramer R, Rivera A, Hohl T . Immune responses against Aspergillus fumigatus: what have we learned?. Curr Opin Infect Dis. 2011; 24(4):315-22. PMC: 3733365. DOI: 10.1097/QCO.0b013e328348b159. View

Guo Y, Chen Y, Wang K, Qin S, Wu C, Kong J . Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest. 2010; 138(4):817-24. DOI: 10.1378/chest.10-0488. View

Spriet I, Lagrou K, Maertens J, Willems L, Wilmer A, Wauters J . Plasmalyte: No Longer a Culprit in Causing False-Positive Galactomannan Test Results. J Clin Microbiol. 2016; 54(3):795-7. PMC: 4767971. DOI: 10.1128/JCM.02813-15. View

Kanjanapan Y, Yip D . Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy. Cancer Med. 2020; 9(23):9027-9035. PMC: 7724496. DOI: 10.1002/cam4.3532. View

Waldeck F, Boroli F, Suh N, Wendel Garcia P, Flury D, Notter J . Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study. Eur J Clin Microbiol Infect Dis. 2020; 39(10):1915-1923. PMC: 7266735. DOI: 10.1007/s10096-020-03923-7. View

Morelli T, Fujita K, Redelman-Sidi G, Elkington P . Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2021; 77(3):304-311. PMC: 8867274. DOI: 10.1136/thoraxjnl-2021-217260. View

Dowdells C, Jones R, Mattey M, Bencina M, Legisa M, Mousdale D . Gluconic acid production by Aspergillus terreus. Lett Appl Microbiol. 2010; 51(3):252-7. DOI: 10.1111/j.1472-765X.2010.02890.x. View

Arias M, Santiago L, Vidal-Garcia M, Redrado S, Lanuza P, Comas L . Preparations for Invasion: Modulation of Host Lung Immunity During Pulmonary by Gliotoxin and Other Fungal Secondary Metabolites. Front Immunol. 2018; 9:2549. PMC: 6232612. DOI: 10.3389/fimmu.2018.02549. View

Mercier T, Castagnola E, Marr K, Wheat L, Verweij P, Maertens J . Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. Clin Infect Dis. 2021; 72(Suppl 2):S89-S94. DOI: 10.1093/cid/ciaa1786. View

10.

Schauwvlieghe A, Rijnders B, Philips N, Verwijs R, Vanderbeke L, van Tienen C . Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018; 6(10):782-792. DOI: 10.1016/S2213-2600(18)30274-1. View

11.

Holding K, Dworkin M, Wan P, Hanson D, Klevens R, Jones J . Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis. 2000; 31(5):1253-7. DOI: 10.1086/317452. View

12.

Latge J, Kobayashi H, Debeaupuis J, Diaquin M, Sarfati J, Wieruszeski J . Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun. 1994; 62(12):5424-33. PMC: 303284. DOI: 10.1128/iai.62.12.5424-5433.1994. View

13.

Kuo C, Wang S, Tsai H, Su P, Cia C, Lai C . Invasive pulmonary aspergillosis is associated with cytomegalovirus viremia in critically ill patients - A retrospective cohort study. J Microbiol Immunol Infect. 2021; 55(2):291-299. DOI: 10.1016/j.jmii.2021.03.005. View

14.

Redelman-Sidi G, Michielin O, Cervera C, Ribi C, Aguado J, Fernandez-Ruiz M . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors,.... Clin Microbiol Infect. 2018; 24 Suppl 2:S95-S107. PMC: 5971148. DOI: 10.1016/j.cmi.2018.01.030. View

15.

Wiener R, Schwartz L, Woloshin S, Welch H . Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011; 155(3):137-44. PMC: 3150964. DOI: 10.7326/0003-4819-155-3-201108020-00003. View

16.

Zhou W, Li H, Zhang Y, Huang M, He Q, Li P . Diagnostic Value of Galactomannan Antigen Test in Serum and Bronchoalveolar Lavage Fluid Samples from Patients with Nonneutropenic Invasive Pulmonary Aspergillosis. J Clin Microbiol. 2017; 55(7):2153-2161. PMC: 5483917. DOI: 10.1128/JCM.00345-17. View

17.

Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L . Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clin Infect Dis. 2020; 73(11):e3606-e3614. PMC: 7454393. DOI: 10.1093/cid/ciaa1065. View

18.

Fujita K, Kim Y, Kanai O, Yoshida H, Mio T, Hirai T . Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respir Med. 2019; 146:66-70. DOI: 10.1016/j.rmed.2018.11.021. View

19.

Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z . Current treatments for non-small cell lung cancer. Front Oncol. 2022; 12:945102. PMC: 9403713. DOI: 10.3389/fonc.2022.945102. View

20.

Detterbeck F, Boffa D, Kim A, Tanoue L . The Eighth Edition Lung Cancer Stage Classification. Chest. 2016; 151(1):193-203. DOI: 10.1016/j.chest.2016.10.010. View